Most of the chemotherapeutic agents are unable to penetrate the blood–brain barrier. EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach ...

You can also develop brain mets with some forms of non-small-cell lung cancer (NSCLC) caused by changes (or mutations) in certain genes, such as: EGFR-positive lung cancer Anaplastic lymphoma ...

This study, they added, addresses this gap, demonstrating that even a short history of cognitive impairment can increase death risk by nearly 50% in younger adult patients (mean age 60.5 years) with ...

The estimated glomerular filtration rate (eGFR) is a blood test to assess kidney function. The formula for calculating eGFR takes the patient’s body size, age, and sex into account to predict ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

Rapid eGFR decline occurred in 23% of patients on ... preventing vascular diseases in the heart, brain and musculoskeletal systems,” Stein I. Hallan, of the department of clinical and molecular ...

The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Most of the chemotherapeutic agents are unable to penetrate the blood–brain barrier. EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach ...